Obinutuzumab Added to Chemotherapy Reduced Risk of Progression in Follicular Lymphoma
December 5th 2016Combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.
Read More
Pembrolizumab Triplet Induces Durable Responses for Multiple Myeloma
December 5th 2016Pembrolizumab (Keytruda), pomalidomide (Pomalyst), and dexamethasone had an objective response rate of 65% and a very good partial response or better rate of 29% for patients with relapsed/refractory multiple myeloma, according to phase II findings presented at the 2016 ASH Annual Meeting.
Read More
Conversion to Minimal Residual Disease Triples With Daratumumab in Relapsed Myeloma
December 5th 2016Data from a prospective assessment of minimal residual disease from the phase III CASTOR and POLLUX studies demonstrated at least a 3-fold increase in conversion to negative MRD status with the addition of daratumumab (Darzalex) to standard-of-care regimens in the treatment of patients with relapsed/refractory multiple myeloma.
Read More
Vadastuximab Talirine Shows Early Signs of Efficacy in Patients With AML
December 5th 2016With treatment for newly diagnosed acute myeloid leukemia remaining essentially unchanged over the last 4 decades, researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for these patients.
Read More
Brentuximab Vedotin Induces Impressive Responses in Cutaneous T-cell Lymphoma
December 5th 2016Brentuximab vedotin (Adcetris) induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial.
Read More
Improved Survival for Younger MCL Patients on Rituximab Maintenance Therapy
December 5th 2016Younger patients with mantle cell lymphoma lived significantly longer and without disease progression or clinical events when they received rituximab maintenance therapy after stem cell transplantation.
Read More
Consolidation to VRD Improves PFS in Patients With Newly Diagnosed Myeloma
December 5th 2016Consolidation therapy with bortezomib/lenalidomide/dexamethasone (VRD) followed by maintenance with lenalidomide until progression or toxicity showed promising results over maintenance alone for patients with transplant-eligible multiple myeloma (NDMM) up to 65 years old, according to a final analysis of the EMN02 trial.
Read More
Nivolumab/Ibrutinib Combo Shows Encouraging Activity for Richter Transformation
December 4th 2016Treatment with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica) showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.
Read More
CPX-351 Before Transplant Improves Survival for Older Patients With AML
December 4th 2016An exploratory subgroup analysis of older patients with high-risk acute myeloid leukemia who took the liposomal formulation CPX-351 (Vyxeos) before allogeneic hematopoietic cell transplantation demonstrated that the drug improves overall survival and reduces the risk of early death.
Read More
An Overview of the PROGRESS II Trial in Acute Leukemia and Myelodysplastic Syndrome
December 4th 2016Miguel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, and director, Adult Bone Marrow Transplantation Fellowship Program, gives an overview of the PROGRESS II trial in acute leukemia and myelodysplastic syndrome during the ASH Annual Meeting.
Watch
Nivolumab Combinations Feasible for Newly Diagnosed GBM
November 20th 2016The PD-1 inhibitor nivolumab was successfully combined with radiotherapy alone or concurrently with temozolomide for patients with newly-diagnosed glioblastoma multiforme in cohorts 1c and 1d from the phase I CheckMate-143 study.
Read More
Novel Gene Therapy Effective for High-Grade Gliomas
November 19th 2016Treatment with the novel regimen of Toca 511 and Toca FC demonstrated a median overall survival of 13.6 months for patients with high-grade gliomas, representing a marked improvement over historical median survivals of 7.2 to 9.2 months.<br />
Read More
Impact of the KEYNOTE-045 Study Comparing Pembrolizumab and Chemotherapy in Bladder Cancer
November 17th 2016Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.
Watch
An Overview of Clinical Trials Investigating Immunotherapy Combos, Sequencing in Melanoma
November 16th 2016Igor Puzanov, MD, professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses 2 clinical trials investigating immunotherapy combinations and sequencing in melanoma.
Watch
Effects of Stress on Ovarian Cancer, Other Cancer Types
November 16th 2016Susan Lutgendorf, PhD, professor, Department of Psychological and Brain Sciences, The University of Iowa, discusses a study investigating the effects of stress on immune response and tumor microenvironment in ovarian cancer and other cancer types.
Watch
PD-1/CTLA-4 Inhibitor Combination Highly Effective for Metastatic Bladder Cancer
November 15th 2016Treatment with the combination of nivolumab and ipilimumab at selected doses led to a high response rate and marked improvements in overall survival for patients with pretreated metastatic urothelial carcinoma.
Read More